DOCSLIB.ORG

Heart Failure Drug Proscillaridin a Targets MYC Overexpressing Leukemia Through Global Loss of Lysine Acetylation Elodie M

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Heart Failure Drug Proscillaridin a Targets MYC Overexpressing Leukemia Through Global Loss of Lysine Acetylation Elodie M Da Costa et al. Journal of Experimental & Clinical Cancer Research (2019) 38:251 https://doi.org/10.1186/s13046-019-1242-8 RESEARCH Open Access Heart failure drug proscillaridin A targets MYC overexpressing leukemia through global loss of lysine acetylation Elodie M. Da Costa1,2, Gregory Armaos1,2, Gabrielle McInnes1,2, Annie Beaudry2, Gaël Moquin-Beaudry1,2, Virginie Bertrand-Lehouillier2,3, Maxime Caron2, Chantal Richer2, Pascal St-Onge2, Jeffrey R. Johnson4, Nevan Krogan4, Yuka Sai5, Michael Downey5, Moutih Rafei1,6,7, Meaghan Boileau8, Kolja Eppert8, Ema Flores-Díaz9, André Haman9, Trang Hoang1,9, Daniel Sinnett2,10, Christian Beauséjour1,2, Serge McGraw2,3,11 and Noël J.-M. Raynal1,2* Abstract Background: Cardiac glycosides are approved for the treatment of heart failure as Na+/K+ pump inhibitors. Their repurposing in oncology is currently investigated in preclinical and clinical studies. However, the identification of a specific cancer type defined by a molecular signature to design targeted clinical trials with cardiac glycosides remains to be characterized. Here, we demonstrate that cardiac glycoside proscillaridin A specifically targets MYC overexpressing leukemia cells and leukemia stem cells by causing MYC degradation, epigenetic reprogramming and leukemia differentiation through loss of lysine acetylation. Methods: Proscillaridin A anticancer activity was investigated against a panel of human leukemia and solid tumor cell lines with different MYC expression levels, overexpression in vitro systems and leukemia stem cells. RNA- sequencing and differentiation studies were used to characterize transcriptional and phenotypic changes. Drug- induced epigenetic changes were studied by chromatin post-translational modification analysis, expression of chromatin regulators, chromatin immunoprecipitation, and mass-spectrometry. Results: At a clinically relevant dose, proscillaridin A rapidly altered MYC protein half-life causing MYC degradation and growth inhibition. Transcriptomic profile of leukemic cells after treatment showed a downregulation of genes involved in MYC pathways, cell replication and an upregulation of hematopoietic differentiation genes. Functional studies confirmed cell cycle inhibition and the onset of leukemia differentiation even after drug removal. Proscillaridin A induced a significant loss of lysine acetylation in histone H3 (at lysine 9, 14, 18 and 27) and in non- histone proteins such as MYC itself, MYC target proteins, and a series of histone acetylation regulators. Global loss of acetylation correlated with the rapid downregulation of histone acetyltransferases. Importantly, proscillaridin A demonstrated anticancer activity against lymphoid and myeloid stem cell populations characterized by MYC overexpression. Conclusion: Overall, these results strongly support the repurposing of proscillaridin A in MYC overexpressing leukemia. Keywords: Cardiac glycosides, Proscillaridin A, MYC, Leukemia, Lysine acetylation, Chromatin remodelling, Lysine acetyltransferase, Leukemia stem cells * Correspondence: [email protected] 1Département de pharmacologie et physiologie, Université de Montréal, Montréal, (Québec), Canada 2Sainte-Justine University Hospital Research Center (7.17.020), 3175, Chemin de la Côte-Sainte-Catherine, Montréal, (Québec) H3T 1C5, Canada Full list of author information is available at the end of the article © The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. Da Costa et al. Journal of Experimental & Clinical Cancer Research (2019) 38:251 Page 2 of 14 Background their narrow therapeutic window. Indeed, maximal plas- MYC (c-MYC) transcription factor is a driver of onco- matic level is around 10 nanomolar, due to cardiac toxic- genic programs. It contributes to gene deregulation in ities [17–19]. Several in vitro and in vivo studies tested cancer by promoting expression of genes involved in cell their anticancer activity at supra-pharmacological doses, proliferation [1]. High MYC expression drives tumor ini- which are not reachable in humans; in particular, in tiation, progression, and maintenance and is associated rodents who can tolerate high doses of these drugs due to with aggressive cancers and poor prognoses [2]. MYC is structural differences in Na+/K+ pump as compared to a potent driver in leukemia inducing cell proliferation human [19–21]. Since the repurposing of cardiac glyco- and blocking cell differentiation [3]. Moreover, MYC sides is restricted to the low nanomolar range, we sought contributes to long-term self-renewal of leukemic stem to identify cancer types highly sensitive to these drugs. To cells [4]. Conversely, genetic suppression of MYC in do so, we screened a panel of human cancer cell lines with transgenic mouse models induces differentiation and cell proscillaridin A, which was identified as the most potent growth arrest of leukemic cells [5, 6]. Therefore, target- cardiac glycoside in our previous screens [15, 16]. Proscil- ing MYC addiction in leukemia is a major therapeutic laridin A produced antiproliferative effects with a prefer- goal. Since MYC lacks a catalytic site, its direct inhibition ential selectivity towards MYC overexpressing leukemia has been extremely challenging. Indirect MYC inhibition cells. We demonstrated that proscillaridin A produced a demonstrated therapeutic efficacy with bromodomain global loss of acetylation in chromatin and MYC itself, pro- inhibitors (such as JQ1 or THZ1), by blocking MYC tran- ducing epigenetic effects and MYC downregulation. These scriptional effects [7–9]. Unfortunately, cancer cells, such results provide compelling evidence for the repurposing of as leukemia, breast and ovarian cancers, develop resistance cardiac glycoside proscillaridin A against leukemia driven to these inhibitors by compensatory mechanisms using by MYC oncogenic signature. other bromodomain containing proteins or kinome repro- gramming [10, 11]. Together, these studies highlight the Materials and methods need to develop new strategies to abrogate MYC Cell culture and drug treatments addiction in cancer. A panel of 14 human cancer cell lines and hTERT/ MYC stability is regulated by post-translational modi- SV40ER-immortalized human primary fibroblasts were fications and MYC acetylation increases its stability [12]. used in the study. Leukemia cell lines MOLT-4 and REH The deposition of acetyl groups on lysine residues is cat- were transduced with MYC lentivirus and hTERT/ alyzed by lysine acetyltransferases (KATs), which acetyl- SV40ER-immortalized human primary fibroblasts were V12 V12 ate also histone proteins causing chromatin opening and transduced with MYC, RAS or MYC and RAS len- gene activation [13]. Pharmacological inhibition of KATs tiviruses. MYC lentivirus MYC_pLX307 was a gift from represents an interesting strategy to target indirectly William Hahn & Sefi Rosenbluh (Addgene plasmid # V12 MYC by blocking upstream mechanisms involved in its 98363). RAS lentivirus was a gift from Dr. Christian stability. However, KATs have overlapping targets and Beauséjour laboratory. Cell types and culture conditions commercially available KAT inhibitors require further are described in Additional file 1 Supplementary Mate- optimization [14]. rials and Methods. Proscillaridin A was purchased from Recently, we reported that cardiac glycosides, which are Santa Cruz Biotechnologies (CAS number: 466–06-8; Na+/K+ pump inhibitors and approved for heart failure purity ≥90%) and cycloheximide was purchased from treatment, exhibit significant epigenetic and anticancer Acros Organics (CAS: 66–81-9; purity ≥95%). IC50 effects [15, 16]. Cardiac glycosides, including digitoxin, values were calculated with GraphPad Prism software. digoxin, lanatoside C, ouabain and proscillaridin A, trig- gered reactivation of epigenetically silenced tumor sup- Protein and histone extractions pressor genes, supporting their repurposing potential [16]. Whole cell proteins were extracted using cold whole-cell Interestingly, all cardiac glycosides produced synergistic lysis buffer (50 mM Tris-Cl pH 7.4, 5 mM EDTA, 250 responses when used in combination with the epigenetic mM NaCl, 50 mM NaF, 0.1% Triton, 0.1 mM Na3VO4, drug decitabine (demethylating agent), further supporting and 1 mM PMSF), supplemented with Complete™ Prote- their epigenetic activity [15]. Several epidemiological stud- ase Inhibitor Cocktail (Roche). Histones were harvested ies argue in favor of repurposing cardiac glycosides in using acid-extraction method with cold Triton Extrac- oncology. Indeed, patients treated with cardiac glycosides tion Buffer (TEB; 0.5% Triton, 2 mM PMSF, 0.02% forheartfailurehavealowerrateofcancerdiagnosisas NaN3, 10 mM sodium butyrate), supplemented with pro- compared to the general population and upon cancer tease inhibitor cocktail. Protein extracts were separated diagnosis; these patients exhibit generally a less aggressive by SDS-PAGE and transferred onto a polyvinyl difluor- disease and respond better to therapy [17]. However,
Load more

Recommended publications
  • Combination of Pretreatments with Acetic Acid and Sodium Methoxide for Efficient Digoxin Preparation from Digitalis Glycosides in Digitalis Lanata Leaves
    Pharmacology & Pharmacy, 2016, 7, 200-207 Published Online May 2016 in SciRes. http://www.scirp.org/journal/pp http://dx.doi.org/10.4236/pp.2016.75026 Combination of Pretreatments with Acetic Acid and Sodium Methoxide for Efficient Digoxin Preparation from Digitalis Glycosides in Digitalis lanata Leaves Yasuhiko Higashi*, Yukari Ikeda, Youichi Fujii Department of Analytical Chemistry, Faculty of Pharmaceutical Sciences, Hokuriku University, Kanazawa, Japan Received 21 April 2016; accepted 28 May 2016; published 31 May 2016 Copyright © 2016 by authors and Scientific Research Publishing Inc. This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/ Abstract We previously developed an HPLC method for determination of lanatoside C, digoxin and α-acetyl- digoxin in digitalis glycosides isolated from Digitalis lanata leaves. Here, we present an improved HPLC-UV method to determine those compounds and deslanoside. We used the improved method to examine the effects of various pretreatments on the amounts of the four compounds isolated from the leaves, with the aim of maximizing the yield of digoxin. Leaves were extracted with 50% methanol, followed by clean-up on a Sep-Pak C18 cartridge prior to HPLC analysis. The amounts of lanatoside C, digoxin and α-acetyldigoxin per 100 mg of the leaves without pretreatment were 115.6, 7.45 and 23.8 μg, respectively (deslanoside was not detected). Pretreatment with acetic ac- id, which activated deglucosylation mediated by digilanidase present in the leaves, increased the amounts of digoxin and α-acetyldigoxin, while lanatoside C and deslanoside were not detected. Pretreatment with sodium methoxide, which hydrolyzed lanatoside C to deslanoside, increased the yields of deslanoside and digoxin, while lanatoside C and α-acetyldigoxin were not detected.
    [Show full text]
  • Chemistry, Spectroscopic Characteristics and Biological Activity of Natural Occurring Cardiac Glycosides
    IOSR Journal of Biotechnology and Biochemistry (IOSR-JBB) ISSN: 2455-264X, Volume 2, Issue 6 Part: II (Sep. – Oct. 2016), PP 20-35 www.iosrjournals.org Chemistry, spectroscopic characteristics and biological activity of natural occurring cardiac glycosides Marzough Aziz DagerAlbalawi1* 1 Department of Chemistry, University college- Alwajh, University of Tabuk, Saudi Arabia Abstract:Cardiac glycosides are organic compounds containing two types namely Cardenolide and Bufadienolide. Cardiac glycosides are found in a diverse group of plants including Digitalis purpurea and Digitalis lanata (foxgloves), Nerium oleander (oleander),Thevetiaperuviana (yellow oleander), Convallariamajalis (lily of the valley), Urgineamaritima and Urgineaindica (squill), Strophanthusgratus (ouabain),Apocynumcannabinum (dogbane), and Cheiranthuscheiri (wallflower). In addition, the venom gland of cane toad (Bufomarinus) contains large quantities of a purported aphrodisiac substance that has resulted in cardiac glycoside poisoning.Therapeutic use of herbal cardiac glycosides continues to be a source of toxicity today. Recently, D.lanata was mistakenly substituted for plantain in herbal products marketed to cleanse the bowel; human toxicity resulted. Cardiac glycosides have been also found in Asian herbal products and have been a source of human toxicity.The most important use of Cardiac glycosides is its affects in treatment of cardiac failure and anticancer agent for several types of cancer. The therapeutic benefits of digitalis were first described by William Withering in 1785. Initially, digitalis was used to treat dropsy, which is an old term for edema. Subsequent investigations found that digitalis was most useful for edema that was caused by a weakened heart. Digitalis compounds have historically been used in the treatment of chronic heart failure owing to their cardiotonic effect.
    [Show full text]
  • Multidose Evaluation of 6,710 Drug Repurposing Library Identifies Potent SARS-Cov-2 Infection Inhibitors in Vitro and in Vivo
    bioRxiv preprint doi: https://doi.org/10.1101/2021.04.20.440626; this version posted April 22, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Multidose evaluation of 6,710 drug repurposing library identifies potent SARS-CoV-2 infection inhibitors In Vitro and In Vivo. JJ Patten1, P. T. Keiser 1, D. Gysi2,3, G. Menichetti 2,3, H. Mori 1, C. J. Donahue 1, X. Gan 2,3, I. Do Valle 2, , K. Geoghegan-Barek 1, M. Anantpadma 1,4, J. L. Berrigan 1, S. Jalloh1, T. Ayazika1, F. Wagner6, M. Zitnik 2, S. Ayehunie6, D. Anderson1, J. Loscalzo3, S. Gummuluru1, M. N. Namchuk7, A. L. Barabasi2,3,8, and R. A. Davey1. Addresses: 1. Department of Microbiology, Boston University School of Medicine and NEIDL, Boston University, Boston, MA, 02118, USA. 2. Center for Complex Network Research, Northeastern University, Boston, Massachusetts 02115, USA. 3. Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA. 4. present address: Analytical Development, WuXi Advanced Therapies, Philadelphia, PA, 19112, USA. 5. Center for the Development of Therapeutics, Broad Institute of Harvard and MIT, Cambridge, MA, 02142, USA. 6. MatTek Corporation, Ashland, MA 01721, USA. 7. Department of Biological Chemistry and Molecular Pharmacology, Blavatnik Institute, Harvard Medical School, Boston, MA. 02115, USA. 8. Department of Network and Data Science, Central European University, Budapest 1051, Hungary. Abstract The SARS-CoV-2 pandemic has caused widespread illness, loss of life, and socioeconomic disruption that is unlikely to resolve until vaccines are widely adopted, and effective therapeutic treatments become established.
    [Show full text]
  • Lanatoside C Induces G2/M Cell Cycle Arrest and Suppresses Cancer Cell Growth by Attenuating MAPK, Wnt, JAK-STAT, and PI3K/AKT/Mtor Signaling Pathways
    biomolecules Article Lanatoside C Induces G2/M Cell Cycle Arrest and Suppresses Cancer Cell Growth by Attenuating MAPK, Wnt, JAK-STAT, and PI3K/AKT/mTOR Signaling Pathways Dhanasekhar Reddy 1 , Ranjith Kumavath 1,* , Preetam Ghosh 2 and Debmalya Barh 3 1 Department of Genomic Science, School of Biological Sciences, Central University of Kerala, Tejaswini Hills, Periya (P.O) Kasaragod 671316, Kerala, India; [email protected] 2 Department of Computer Science, Virginia Commonwealth University, Richmond, VA 23284, USA; [email protected] 3 Centre for Genomics and Applied Gene Technology, Institute of Integrative Omics and Applied Biotechnology (IIOAB), Nonakuri, Purba Medinipur 721172, West Bengal, India; [email protected] * Correspondence: [email protected] or [email protected]; Tel.: +91-8547-648-620 Received: 21 October 2019; Accepted: 22 November 2019; Published: 27 November 2019 Abstract: Cardiac glycosides (CGs) are a diverse family of naturally derived compounds having a steroid and glycone moiety in their structures. CG molecules inhibit the α-subunit of ubiquitous transmembrane protein Na+/K+-ATPase and are clinically approved for the treatment of cardiovascular diseases. Recently, the CGs were found to exhibit selective cytotoxic effects against cancer cells, raising interest in their use as anti-cancer molecules. In this current study, we explored the underlying mechanism responsible for the anti-cancer activity of Lanatoside C against breast (MCF-7), lung (A549), and liver (HepG2) cancer cell lines. Using
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2009/0246185 A1 Kishida Et Al
    US 20090246185A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0246185 A1 Kishida et al. (43) Pub. Date: Oct. 1, 2009 (54) CARDIAC DYSFUNCTION-AMELIORATING (30) Foreign Application Priority Data AGENT OR CARDAC FUNCTION-MANTAININGAGENT Mar. 13, 2006 (JP) ................................. 2006-066992 Nov. 21, 2006 (JP) ................................. 2006-314034 (75) Inventors: Hideyuki Kishida, Hyogo (JP); O O Kenji Fujii, Hyogo (JP); Hiroshi Publication Classification Kubo, Hyogo (JP); Kazunori (51) Int. Cl. Hosoe, Hyogo (JP) A6II 3L/22 (2006.01) CD7C 43/23 (2006.01) Correspondence Address: A6IP 9/00 (2006.01) SUGHRUE MION, PLLC (52) U.S. Cl. ........................................ 424/94.1:568/651 2100 PENNSYLVANIA AVENUE, N.W., SUITE 8OO (57) ABSTRACT WASHINGTON, DC 20037 (US) An object of the present invention is to provide a highly safe oral composition Superior in a cardiac dysfunction-amelio (73) Assignee: KANEKA CORPORATION, rating or cardiac function-maintaining action. The present OSAKA-SHI, OSAKA (JP) inventors have conducted intensive studies in an attempt to solve the aforementioned problems and found that use of (21) Appl. No.: 12/282,448 particularly, reduced coenzyme Q10 from among highly safe coenzyme Q affords a composition useful for amelioration of (22) PCT Filed: Mar. 9, 2007 cardiac dysfunction and maintenance of cardiac function. Accordingly, the present invention provides a cardiac dys (86). PCT No.: PCT/UP2007/O54.643 function-ameliorating agent or cardiac function-maintaining agent containing reduced coenzyme Qas an active ingredient, S371 (c)(1), and a pharmaceutical product, a food, an animal drug, a feed (2), (4) Date: Dec. 23, 2008 and the like, which contain the agent.
    [Show full text]
  • Eiichi Kimura, MD, Department of Internal Medicine, Nippon Medical
    Effect of Metildigoxin (ƒÀ-Methyldigoxin) on Congestive Heart Failure as Evaluated by Multiclinical Double Blind Study Eiichi Kimura,* M.D. and Akira SAKUMA,** Ph.D. In Collaboration with Mitsuo Miyahara, M.D. (Sapporo Medi- cal School, Sapporo), Tomohiro Kanazawa, M.D. (Akita Uni- versity School of Medicine, Akita), Masato Hayashi, M.D. (Hiraga General Hospital, Akita), Hirokazu Niitani, M.D. (Showa Uni- versity School of Medicine, Tokyo), Yoshitsugu Nohara, M.D. (Tokyo Medical College, Tokyo), Satoru Murao, M.D. (Faculty of Medicine, University of Tokyo, Tokyo), Kiyoshi Seki, M.D. (Toho University School of Medicine, Tokyo), Michita Kishimoto, M.D. (National Medical Center Hospital, Tokyo), Tsuneaki Sugi- moto, M.D. (Faculty of Medicine, Kanazawa University, Kana- zawa), Masao Takayasu, M.D. (National Kyoto Hospital, Kyoto), Hiroshi Saimyoji, M.D. (Faculty of Medicine, Kyoto University, Kyoto), Yasuharu Nimura, M.D. (Medical School, Osaka Uni- versity, Osaka), Tatsuya Tomomatsu, M.D. (Kobe University, School of Medicine, Kobe), and Junichi Mise, M.D. (Yamaguchi University, School of Medicine, Ube). SUMMARY The efficacy on congestive heart failure of metildigoxin (ƒÀ-methyl- digoxin, MD), a derivative of digoxin (DX), which had a good absorp- tion rate from digestive tract, was examined in a double blind study using a group comparison method. After achieving digitalization with oral MD or intravenous deslanoside in the non-blind manner, mainte- nance treatment was initiated and the effects of orally administered MD and DX were compared. MD was administered in 44 cases , DX in 42. The usefulness of the drug was evaluated after 2 weeks , taking into account the condition of the patient and the ease of administration .
    [Show full text]
  • Radioimmunoassay
    Radioimmunoassay Measurement of Serum Cardiac Glycoside Levels: Using Pharmacologic Principles to Solve Crossreactivity Problems Thomas J. Persoon The University of Iowa, Iowa City, Iowa Laboratories performing analyses for serum cardiac Results glycosides are sometimes faced with the problem of dis­ Data collected in our laboratory are similar to those tinguishing between digoxin and digitoxin in a specimen. published by Kuno-Sakai. Tables 3 and 4 show the The antibodies to the cardiac glycosides supplied with measured concentrations of digoxin and digitoxin from radioimmunoassay kits for these drugs have some patient sera known to contain only one drug. Figure 1 measurable degree of cross reactivity. Therapeutic levels is a plot of measured digoxin levels versus actual of digitoxin are approximately ten times greater than digitoxin concentration of serum digitoxin standards. those of digoxin, and the half-lives of these drugs in The slope and intercept of the line were determined by serum differ by a factor of four. These facts have been the linear least-squares technique. combined into a series of rules which allow the technologist to distinguish between digoxin and digitoxin Discussion in a sample and provide a level of the drug that has been corrected for crossreactivity. Figure 2 shows the chemical structures of four cardiac glycosides: digoxin, digitoxin, cedilanid, and In 1972 Edmonds et al. ( 1) published data on the crossreactivity of digitoxin in the digoxin radioim­ TABLE 1. Crossreactivity of Digitoxin in Digoxin RIA munoassay (Tables 1 and 2). They showed the slopes Measured level of of digoxin-digitoxin cross reactivity plots to be linear. Digitoxin added (ng/mll digoxin (ng/mll Kuno-Sakai et al.
    [Show full text]
  • Quo Vadis Cardiac Glycoside Research?
    toxins Review Quo vadis Cardiac Glycoside Research? Jiˇrí Bejˇcek 1, Michal Jurášek 2 , VojtˇechSpiwok 1 and Silvie Rimpelová 1,* 1 Department of Biochemistry and Microbiology, University of Chemistry and Technology Prague, Technická 5, Prague 6, Czech Republic; [email protected] (J.B.); [email protected] (V.S.) 2 Department of Chemistry of Natural Compounds, University of Chemistry and Technology Prague, Technická 3, Prague 6, Czech Republic; [email protected] * Correspondence: [email protected]; Tel.: +420-220-444-360 Abstract: AbstractCardiac glycosides (CGs), toxins well-known for numerous human and cattle poisoning, are natural compounds, the biosynthesis of which occurs in various plants and animals as a self-protective mechanism to prevent grazing and predation. Interestingly, some insect species can take advantage of the CG’s toxicity and by absorbing them, they are also protected from predation. The mechanism of action of CG’s toxicity is inhibition of Na+/K+-ATPase (the sodium-potassium pump, NKA), which disrupts the ionic homeostasis leading to elevated Ca2+ concentration resulting in cell death. Thus, NKA serves as a molecular target for CGs (although it is not the only one) and even though CGs are toxic for humans and some animals, they can also be used as remedies for various diseases, such as cardiovascular ones, and possibly cancer. Although the anticancer mechanism of CGs has not been fully elucidated, yet, it is thought to be connected with the second role of NKA being a receptor that can induce several cell signaling cascades and even serve as a growth factor and, thus, inhibit cancer cell proliferation at low nontoxic concentrations.
    [Show full text]
  • Studies on Myocardial Metabolism. V. the Effects of Lanatoside-C on the Metabolism of the Human Heart
    STUDIES ON MYOCARDIAL METABOLISM. V. THE EFFECTS OF LANATOSIDE-C ON THE METABOLISM OF THE HUMAN HEART J. M. Blain, … , A. Siegel, R. J. Bing J Clin Invest. 1956;35(3):314-321. https://doi.org/10.1172/JCI103280. Research Article Find the latest version: https://jci.me/103280/pdf STUDIES ON MYOCARDIAL METABOLISM. V. THE EFFECTS OF LANATOSIDE-C ON THE METABOLISM OF THE HUMAN HEART 1 By J. M. BLAIN, E. E. EDDLEMAN, A. SIEGEL, AND R. J. BING (From the Departments of Experimental Medicine and Clinical Physiology, The Medical College of Alabama, Birmingham, Alabama, and the Veterans' Administration Hospital, Birmingham, Ala.) (Submitted for publication Septenber 6, 1955; accepted November 16, 1955) Since 1785 when Withering undertook the first this method should aid in elucidating the meta- systemic study of the effects of digitalis, a large bolic pathways within the heart muscle; thus reac- amount of data has been accumulated describing tions determined by more precise in vitro methods its pharmacological effects. Despite intensive could be re-evaluated in the light of data obtained study, the underlying mechanism responsible for on the human heart in vivo. the beneficial results in patients with heart failure The various cardiac glycosides differ in time of remains obscure. Although digitalis in small doses onset and persistence of action. Lanatoside-C, the may affect the heart rate through its vagal effect, preparation used in this study, is a purified deriva- it is agreed that the predominant action of this tive of digitalis lanata which can be given intra- drug is on the heart muscle directly (1).
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Profiling and Structural Analysis of Cardenolides in Two Species of Digitalis Using Liquid Chromatography Coupled with High-Resolution Mass Spectrometry
    bioRxiv preprint doi: https://doi.org/10.1101/864959; this version posted December 5, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. Profiling and structural analysis of cardenolides in two species of Digitalis using liquid chromatography coupled with high-resolution mass spectrometry Baradwaj Gopal Ravi1†, Mary Grace E. Guardian2†, Rebecca Dickman2, Zhen Q. Wang1* 1Department of Biological Sciences, University at Buffalo, State University of New York, Buffalo, NY 14260, United States 2Department of Chemistry, Chemistry Instrumentation Center, University at Buffalo, State University of New York, Buffalo, NY 14260, United States †These authors contributed equally to this work. *Correspondent author: Tel: (+1)7166454969 [email protected] Keywords: cardiac glycoside; foxglove; Digitalis purpurea; Digitalis lanata; digoxin; digitoxin Abstract Plants of the Digitalis genus contain a cocktail of cardenolides commonly prescribed to treat heart failure. Cardenolides in Digitalis extracts have been conventionally quantified by high- performance liquid chromatography yet the lack of structural information compounded with possible co-eluents renders this method insufficient for analyzing cardenolides in plants. The goal of this work is to structurally characterize cardiac glycosides in fresh-leaf extracts using liquid chromatography coupled with tandem mass spectrometry (LC/MS/MS) that provides exact masses. Fragmentation of cardenolides is featured by sequential loss of sugar units while the steroid aglycon moieties undergo stepwise elimination of hydroxyl groups, which distinguishes different aglycones. The sequence of elution follows diginatigenindigoxigeningitoxigeningitaloxigenindigitoxigenin for cardenolides with the same sugar units but different aglycones using a reverse-phase column.
    [Show full text]
  • Ouabain - the Insulin of the Heart Hauke Fürstenwerth
    Ouabain - The Insulin of the Heart Hauke Fürstenwerth To cite this version: Hauke Fürstenwerth. Ouabain - The Insulin of the Heart. International Journal of Clinical Practice, Wiley, 2010, 64 (12), pp.1591. 10.1111/j.1742-1241.2010.02395.x. hal-00599542 HAL Id: hal-00599542 https://hal.archives-ouvertes.fr/hal-00599542 Submitted on 10 Jun 2011 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. International Journal of Clinical Practice For PeerOuabain – TheReview Insulin of the HeartOnly Journal: International Journal of Clinical Practice Manuscript ID: IJCP-12-09-0760.R1 Manuscript Type: Perspective Date Submitted by the 18-Jan-2010 Author: Complete List of Authors: Fürstenwerth, Hauke; Hauke Fürstenwerth, consultant Specialty area: International Journal of Clinical Practice Page 1 of 9 International Journal of Clinical Practice 1 2 Title: Ouabain – The Insulin of the Heart 3 4 Author: Dr. Hauke Fürstenwerth 5 6 Unterölbach 3A 7 D-51381 Leverkusen 8 Germany 9 Phone: +49-2171-733740 10 e-mail: [email protected] 11 12 corresponding author: Dr.
    [Show full text]